Core Viewpoint - Daré Bioscience has received FDA clearance for its investigational drug DARE-HPV, which aims to treat persistent high-risk HPV infections, marking a significant advancement in women's health as there are currently no FDA-approved pharmacologic treatments for HPV [1][5][8] Company Overview - Daré Bioscience is a health biotech company focused on addressing gaps in women's health through innovative solutions backed by rigorous research [9][10] - The company aims to provide evidence-based therapies for various women's health issues, including HPV infections, which have historically lacked effective treatment options [10] Product Development - DARE-HPV is a non-surgical, localized, self-administered therapy designed to clear persistent high-risk HPV infections, which are responsible for nearly all cervical cancer cases in the U.S. [2][3][8] - The drug targets the virus directly, potentially redefining the treatment paradigm for cervical disease prevention by intervening before precancerous changes occur [2][5] Clinical Study and Funding - The planned Phase 2 clinical study will evaluate the safety and antiviral activity of DARE-HPV in women with persistent high-risk HPV infection, supported by a $10 million contract from the Advanced Research Projects Agency for Health (ARPA-H) [5][6] - The company has received $6.5 million of the funding to date and is preparing to initiate the study in 2026 [5][6] Market Need - Persistent high-risk HPV infection represents a substantial unmet medical need, as current standard care involves monitoring without treating the virus, leading to significant physical and emotional burdens for women [4][6] - The lack of effective treatments has resulted in women being subjected to costly and burdensome "watchful waiting" visits, contributing to disparities in cervical cancer outcomes [5][6]

Live webcast of event on February 27 at 8:00 a.m. ET will include participation of globally renowned gynecological oncology KOLs from the US and EU KOL panel to discuss maturing data from the ACR-368 registrational-intent trial, including recently disclosed promising results in serous EC, in the context of high unmet need in EC Panos Konstantinopoulos, M.D., Ph.D., Dana-Farber Cancer Institute, professor, Harvard Medical School, will deliver late-breaking oral presentation of ACR-368 interim clinical data a ...

Core Insights - Recursion, a clinical stage TechBio company, will be featured in a Lightning Talk at the NVIDIA GTC AI Conference, focusing on the integration of AI, automation, and robotics in drug discovery and development [1][4] Company Overview - Recursion is a leading TechBio company that decodes biology to improve lives, utilizing a platform called Recursion OS to generate one of the largest proprietary biological and chemical datasets [5] - The company operates sophisticated integrated wet and dry labs for AI drug discovery, generating millions of multi-omic data points weekly to enhance the drug discovery process [3][5] - Recursion's operations are supported by its powerful supercomputer, BioHive-2, which facilitates end-to-end improvements in drug discovery, including biological discoveries, precision drug design, and optimized clinical trials [3][5] Collaboration and Technology - Recursion is collaborating with HighRes Biosolutions to develop self-driving, high-throughput labs using advanced automation and orchestration technologies [2] - The collaboration leverages HighRes technologies such as robotic perception and digital twins of laboratory environments, which are essential for creating self-driving laboratories [2] Industry Impact - The advancements in AI and accelerated computing are pushing the boundaries of drug discovery, with NVIDIA's involvement highlighting the transition from concept to reality in Physical AI [4]

Conference Call and Webcast Scheduled for Monday, March 2, 2026 at 10:00 AM ETPRINCETON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourth quarter and full-year 2025 financial results on Monday, March 2nd , 2026, prior to the open of the stock market. The announcement will be followed by a live audio webcast and co ...

BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting and hosting 1x1 investor meetings at the 46th Annual TD Cowen Health Care Conference in Boston, MA. Presentation: Monday, March 2, 2026 at 9:50am – 10:20 am ETLocation: Regis A live webcast and archived replay of the presentation will be remain available for a period of 90 days on the Company’s website at: https: ...

Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should re ...

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from two presentations at the Conference on Retroviruses and Opportunistic Infections (CROI), being held February 22 – 25, 2026 in Denver, Colorado. The pevifoscorvir sodium presentation highlights the Phase 1 monotherapy study of pev ...

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will present and participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, in Boston, Massachusetts; presentation at 9:10am Eastern TimeLeerink An ...

Core Viewpoint - Crescent Biopharma is focused on advancing innovative cancer therapies and will present at key investor conferences in March 2026 [1][3]. Company Overview - Crescent Biopharma aims to become a leading oncology company by developing next-generation therapies for cancer patients [2]. - The company's clinical-stage pipeline includes a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates (ADCs) [2]. - Crescent intends to leverage multiple modalities and established targets to develop transformative therapies for various solid tumors [2]. Upcoming Events - Crescent Biopharma will participate in the TD Cowen 46th Annual Health Care Conference on March 2, 2026, at 3:50 p.m. ET in Boston [3]. - The company will also be featured in the Leerink Partners 2026 Global Healthcare Conference on March 11, 2026, at 8:40 a.m. ET in Miami [3].

Core Viewpoint - ADC Therapeutics has amended its royalty purchase agreement with HealthCare Royalty, enhancing strategic flexibility and reducing financial obligations related to potential change of control events [2][3]. Financial Terms - The change of control payment has been reduced from $750 million to $150 million until the end of 2027, and to $200 million thereafter [2][6]. - HealthCare Royalty will continue to receive royalties on sales by any acquirer until the original royalty cap is reached [2]. - HealthCare Royalty has been granted warrants to purchase approximately 9.8 million common shares at an exercise price of $3.81 per share, exercisable until December 31, 2030, with a lock-up period until the end of 2027 [2][3]. Product Overview - ZYNLONTA is a CD19-directed antibody drug conjugate that targets and kills tumor cells by delivering a potent payload that binds to DNA [5]. - The FDA and EMA have approved ZYNLONTA for treating adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy [7][9]. Market Potential - ADC Therapeutics anticipates significant growth for ZYNLONTA starting in 2027, with potential peak revenue in the U.S. estimated to reach between $600 million to $1 billion annually, assuming compendia inclusion and regulatory approval [3]. - The confidence in ZYNLONTA's potential is bolstered by existing and upcoming clinical data, particularly in diffuse large B-cell lymphoma and other indolent lymphomas [3]. Company Background - ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates, focused on transforming treatment for patients through its portfolio, including ZYNLONTA [8]. - The company is headquartered in Lausanne, Switzerland, with operations in New Jersey, and is committed to driving innovation in ADC development [10].